Elsiglutide (ZP 1846) is a synthetic 39-amino acid glucagon-like peptide-2 (GLP-2) analogue. Upon subcutaneous administration, elsiglutide binds to GLP-2 receptors and thereby promotes proliferation of epithelial cells. Elsiglutide prevents or reduces the occurrence of gastrointestinal damage caused by chemotherapeutic agents, including gastrointestinal mucositis and chemotherapy-induced diarrhea (CID). Elsiglutide is being developed by Helsinn Healthcare, for the prevention of chemotherapy-induced diarrhoea.